Literature DB >> 16250904

The ubiquitin-proteasome system and neurodegenerative disorders.

Robert Layfield1, James Lowe, Lynn Bedford.   

Abstract

As in all other mammalian tissues, the UPS (ubiquitin-proteasome system) is fundamental to normal brain function. A consistent feature of the major human neurodegenerative disorders is the accumulation of disease-related proteins, in non-native conformations, as protein aggregates within neurons or glial cells. Often the proteins in these aggregates are post-translationally conjugated with ubiquitin, suggesting a possible link between pathological protein-aggregation events in the nervous system and dysfunction of the UPS. Genetic evidence clearly demonstrates that disruption of ubiquitin-mediated processes can lead to neurodegeneration; however, the relationship between the UPS and idiopathic neurodegenerative disorders is less clear. In the latter cases, although a number of different mechanisms could potentially contribute to dysfunction of the UPS and promote the neurodegenerative process, whether UPS dysfunction is causally related to disease pathogenesis, or alternatively arises as a result of the pathological state, and indeed whether ubiquitinated inclusions are harmful or beneficial to cells, remains to be clarified.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16250904     DOI: 10.1042/EB0410157

Source DB:  PubMed          Journal:  Essays Biochem        ISSN: 0071-1365            Impact factor:   8.000


  22 in total

1.  Intermediate filament transcription in astrocytes is repressed by proteasome inhibition.

Authors:  Jinte Middeldorp; Willem Kamphuis; Jacqueline A Sluijs; Dalila Achoui; Cathalijn H C Leenaars; Matthijs G P Feenstra; Paula van Tijn; David F Fischer; Celia Berkers; Huib Ovaa; Roy A Quinlan; Elly M Hol
Journal:  FASEB J       Date:  2009-03-30       Impact factor: 5.191

2.  Translational gene mapping of cognitive decline.

Authors:  Beth Wilmot; Shannon K McWeeney; Randal R Nixon; Thomas J Montine; Jamie Laut; Christina A Harrington; Jeffrey A Kaye; Patricia L Kramer
Journal:  Neurobiol Aging       Date:  2006-12-14       Impact factor: 4.673

Review 3.  Proteasome inhibitors and cardiac cell growth.

Authors:  Nadia Hedhli; Christophe Depre
Journal:  Cardiovasc Res       Date:  2009-07-03       Impact factor: 10.787

4.  HSP70 mediates dissociation and reassociation of the 26S proteasome during adaptation to oxidative stress.

Authors:  Tilman Grune; Betül Catalgol; Anke Licht; Gennady Ermak; Andrew M Pickering; Jenny K Ngo; Kelvin J A Davies
Journal:  Free Radic Biol Med       Date:  2011-06-24       Impact factor: 7.376

5.  Immediate early gene-X1 interferes with 26 S proteasome activity by attenuating expression of the 19 S proteasomal components S5a/Rpn10 and S1/Rpn2.

Authors:  Alexander Arlt; Jörg Minkenberg; Marie-Luise Kruse; Frauke Grohmann; Ulrich R Fölsch; Heiner Schäfer
Journal:  Biochem J       Date:  2007-03-01       Impact factor: 3.857

6.  Conserved signal peptide of Notch3 inhibits interaction with proteasome.

Authors:  Yanmei Zhang; Lijun Jia; Soo Jung Lee; Michael M Wang
Journal:  Biochem Biophys Res Commun       Date:  2007-02-05       Impact factor: 3.575

7.  The E163K DJ-1 mutant shows specific antioxidant deficiency.

Authors:  Chenere P Ramsey; Benoit I Giasson
Journal:  Brain Res       Date:  2008-09-16       Impact factor: 3.252

8.  The proteasome function reporter GFPu accumulates in young brains of the APPswe/PS1dE9 Alzheimer's disease mouse model.

Authors:  Yanying Liu; Casey L Hettinger; Dong Zhang; Khosrow Rezvani; Xuejun Wang; Hongmin Wang
Journal:  Cell Mol Neurobiol       Date:  2013-12-21       Impact factor: 5.046

Review 9.  Protein quality control system in neurodegeneration: a healing company hard to beat but failure is fatal.

Authors:  Deepak Chhangani; Amit Mishra
Journal:  Mol Neurobiol       Date:  2013-02-03       Impact factor: 5.590

10.  Compensatory changes in the ubiquitin-proteasome system, brain-derived neurotrophic factor and mitochondrial complex II/III in YAC72 and R6/2 transgenic mice partially model Huntington's disease patients.

Authors:  Hyemyung Seo; Woori Kim; Ole Isacson
Journal:  Hum Mol Genet       Date:  2008-07-17       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.